Lonza

🚀 A new edition of Biologics in Focus is live — bringing you the latest insights shaping biologics development.   In this issue, we explore how integrated, data-driven approaches are accelerating progress from DNA to clinic, with topics including advanced expression systems, scalable AAV manufacturing, machine learning–enabled process insights, and strategies to reduce development timelines while maintaining quality and confidence. You’ll also find expert perspectives on optimizing bioproduction and insights supporting more efficient, scalable biologics development.   👉 Follow the newsletter to stay informed on the latest innovations, scientific advances, and practical insights across the biologics landscape.   If you find it valuable, please share it with your network and help grow our biologics community. #Lonza #CDMO #Biologics #BiologicsInFocus

The strength of Europe’s life science hub lies in its connectivity. Our EMEA Business Development team is currently supporting Venture Road initiatives, strengthening relationships across the Nordics and the UK’s “Golden Triangle” – Oxford, Cambridge, and London. Giovanna Libralon and Christian Richter recently shared their perspectives with Ventures Accelerated, highlighting why stronger collaboration between these regions is essential to accelerate innovation and bring ideas to life faster. ▶️ Curious how interconnected ecosystems are shaping the future of life sciences? Take a look at the conversation.

At the SVG Basel event this week, our CEO Dr. Wolfgang Wienand spoke about Lonza’s role as a "hidden force" in the global healthcare system.   As a CDMO, our work behind the scenes makes a critical difference to our customers and their patients. The pharma and biotech landscape continues to evolve at pace, with the emergence of innovative modalities and growing global demand for outsourcing set against a backdrop of macroeconomic volatility. In this environment, the need for speed, scale, quality and reliability has never been greater - and this is what Lonza‘s unique business model offers to our partners in the pharmaceutical universe.   At Lonza, our vision and purpose remain clear:    We are the pioneer and world leader in the CDMO industry - and we are on a quest to turn our customers‘ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Our thanks go to the SVG Basel for the opportunity to talk about the pharma and CDMO industries, and Lonza’s place in this important ecosystem.   #OneLonza #1Lonza #1L #Lonza #LonzaEngine #LetsDoThis #MakingtheMedicinesofTomorrow #PlaceofUniqueOpportunity #WeAreOneLonza #CDMO #SVGB

Today, we announced a collaboration with Oxford Nanopore Technologies to launch a new approach to modernize GMP quality control for mRNA therapeutics. By combining direct RNA sequencing with machine learning-driven analysis, the solution aims to close the gap between fast-moving mRNA innovation and the slower evolution of analytical methods. Sönke Stocker, Executive Director of R&D mRNA and External Innovation, Specialized Modalities, Lonza, commented: “The launch of this direct RNA sequencing technology represents an important step forward in how mRNA quality control can be performed. By combining nanopore sequencing with machine learning based analysis, we are introducing a simplified, multi-attribute approach that better aligns GMP quality control with the pace and complexity of modern mRNA development, while maintaining the rigor required for regulated manufacturing.” Read more here: https://lnkd.in/eCrw-edH #Lonza #CDMO #mRNA #ONT #PharmaceuticalManufacturing

Bioavailability. Excellence. When solubility limits your molecule, every decision matters. That’s why we take a molecule-first approach - combining deep expertise with applied problem-solving to increase the probability of success and move your API forward. From early-stage challenges to scale-up, our connected experts work across the development journey to unlock bioavailability. ▶️ Explore our SME perspective on overcoming early-stage solubility challenges: https://ow.ly/Tz7L50Z1HCe #Bioavailability #SprayDrying #Solubility #APIDevelopment #CDMO #AdvancedSynthesis

What a week at ASGCT 2026! It was a busy and valuable few days for the Lonza team, with great conversations across the cell and gene therapy community. Thank you to everyone who visited our booth, joined our presentations, attended the One Lonza reception or met with our team during the conference. We’re leaving ASGCT with strong momentum and many valuable conversations to continue. To speak with one of our team, please get in touch https://lnkd.in/eMYDVTmU #Lonza #ASGCT #CDMO

Lonza will be participating to Antibody Engineering & Therapeutics Europe 2026, taking place 27–29 May in Basel, Switzerland. We are proud to contribute to this year’s program with our scientific expertise. Our colleague, Anette Sommer, Head of R&D - Bioconjugates Research, will chair the session: “ADCs & Bioconjugates: ADCs – A Maturing Field or Still Room for Disruption?” on Wednesday, 27 May. Presentations: 🔹Advantage of GlycoConnect® Platform Technology, Clinical Insights and toxSYN® Platform Expansion 👤 Anette Sommer, Head of R&D - Bioconjugates Research 📅 Thursday, 28 May | ⏰ 09:20–09:50 🔹 De-Risking Scale-Up Challenges: A Holistic Approach to ADC Developability and Process Design 👤 Marco Preuss, Project Leader, Process Development Bioconjugates 📅 Friday, 29 May | ⏰ 13:45–14:15 We look forward to engaging with peers and partners to exchange insights and shape the future of ADC development. If you’re attending, we’d be pleased to connect.

BIO International 2026 is almost here, and we’re excited to reconnect with the global biotech community in San Diego.   Across the week, conversations will span the full spectrum of drug development — from early innovation and partnerships through to development, manufacturing, and commercial readiness. It’s a valuable moment to step back, exchange perspectives, and explore what it really takes to move programs forward with confidence in an increasingly complex landscape.   We work alongside our partners at every stage of that journey, helping translate promising science into scalable, reliable solutions, and BIO is always a great opportunity to continue those conversations in person.   If you’ll be there, we’d love to connect, exchange ideas, and hear more about where you’re focusing next.   📅 June 22–25, 2026 📍 San Diego, CA, USA   #BIOInternational2026 #Lonza #Biotech #CDMO #BIO2026

For swissVR, an association of Swiss-based board directors, I interviewed Jean-Marc Huët, chairman of Lonza Group and The HEINEKEN Company Holding NV. Key statements from Jean-Marc included: - “If a board consists only of low-risk profiles, it is unlikely to make the best decisions. We also need adventurous thinkers”. - “I prefer to conduct board evaluations myself, together only with our general counsel.” - “I hold an annual two-week “chair roadshow,” together with the general counsel but without the CEO”. - “We have three key board meetings each year that must be held in person”. - “I genuinely believe the Swiss governance system is among the best”. Links to the German and French versions are in the first comment. Swiss International Society #Lonza #Heineken #JeanMarcHuet #swissVR #PhilippeMonnier

We’re pleased to be at the 55th Organic Process Research & Development Conference, between 20 - 22 May 2026, in Toronto, Canada. A highlight from Lonza: 🎤 Aaron Johnson, PhD, R&D Cheminformatics Data Scientist, will present “AI‑Enhanced Workflows for Modern Drug Development.” The session will explore how AI‑driven approaches can support smarter decision‑making and more efficient development in modern process R&D. 📅 Wednesday, 20 May 2026, 3:00pm GMT-4 | 📍 The Westin Harbour Castle 👉 Connect with our team in advance (https://ow.ly/Ok6Z50YWxlx) to discuss your challenges, join the conversation, or meet us at the conference. #ProcessChemistry #AIinDrugDevelopment #Lonza #ScientificUpdate